Lisa M. Shook, DHPE, MA, MCHES, CCP
- Administrative Director, Comprehensive Sickle Cell Center
- Assistant Professor, UC Department of Pediatrics
About
Biography
I am passionate about improving outcomes for children and adults living with sickle cell disease through my work at the Comprehensive Sickle Cell Center at Cincinnati Children's. My research interests are health education, health disparities, health services, health literacy, newborn screening, sickle cell disease, sickle cell trait, network building and quality improvement.
The health services research and patient/provider education programs that I oversee complement this world-class research and clinical program for sickle cell disease. This includes an Ohio Department of Health-funded newborn screening grant for sickle cell disease and sickle cell trait follow-up, along with community outreach and education.
I also lead the Sickle Treatment and Outcomes Research in the Midwest (STORM) project, an eight-state regional learning network of pediatric and adult providers in Ohio, Indiana, Illinois, Michigan, Minnesota, North Dakota, South Dakota and Wisconsin. This work has been a federally funded Sickle Cell Disease Treatment Demonstration Project since 2014. As part of this, we launched the successful Project Extension for Community Healthcare Outcomes (Project ECHO) that provides monthly telementoring to healthcare providers across the country and world.
I received my doctorate in Health Professions Education in 2020, my master’s degree in Health Education in 2008, and I have been a Master Certified Health Education Specialist since 2012. I have been a researcher for more than 15 years and began working at Cincinnati Children's in 2005.
MA: University of Alabama, Tuscaloosa, AL, 2008.
Certification: Certified Health Education Specialist, 2009; Master Certified Health Education Specialist, 2012.
Services and Specialties
Cancer and Blood Diseases
Research Areas
Cancer and Blood Diseases, Hematology
Publications
A health equity ECHO for clinicians of individuals with SCD. 2024; 1.
Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 2024; 46:e305-e312.
A Mixed-Methods Evaluation of a Project ECHO Program for the Evidence-Based Management of Sickle Cell Disease. International Journal of Environmental Research and Public Health. 2024; 21:530.
Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204:26-28.
Grndad and Disease Modifying Therapy (DMT): Shifts in Dmt Are Seen at the Adolescent/Young Adult Transition in Sickle Cell Disease in a Multi-Site Prospective Registry. Blood. 2023; 142:798.
SCD and COVID-19 Vaccines: What Do Pediatric Patients Want to Know?. Blood. 2023; 142:7199.
A Health Equity Echo for Providers of Children and Adults with Sickle Cell Disease. Blood. 2022; 140:13141-13142.
Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia. Blood. 2022; 140:10857-10859.
The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease. Ethnicity and Health. 2022; 27:833-846.
Expanding a Regional Sickle Cell Disease Project ECHO® to Rapidly Disseminate COVID-19 Education. Advances in Medical Education and Practice. 2022; 13:443-447.
From the Blog
Four Things To Know About Sickle Cell Disease
9/11/2020
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
